FRANKLIN, Tenn. / Oct 30, 2025 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have entered into a definitive agreement to sell their 80% ownership interests in two joint ventures, which respectively own and operate 270-bed Tennova Healthcare - Clarksville and certain ancillary businesses located in Clarksville, Tennessee, to subsidiaries of Vanderbilt University Medical Center (VUMC) for $600 million, subject to certain net working capital and other adjustments. VUMC currently holds a minority ownership interest in these joint ventures and will purchase the remaining ownership interests through this transaction.
The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions.
This transaction is among the additional potential divestitures discussed on the Company’s third quarter 2025 earnings call and in subsequent public appearances.
Leerink Partners is acting as exclusive financial advisor to the Company for the transaction.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. The Company’s subsidiaries own or lease 70 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
| Last Trade: | US$3.79 |
| Daily Change: | -0.06 -1.56 |
| Daily Volume: | 771,401 |
| Market Cap: | US$524.990M |
July 22, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load